Grupo Oncoclinicas sought to ascertain whether Paige Prostate could be used as quality control tool, even when applied in a different setting to where it was developed. Paige Prostate was applied to independent, real-world data from Grupo Oncoclinicas, and its sensitivity, specificity, positive predictive values, and negative predictive values were compared to that of 3 pathologists. 

The study found that:

• At the patient level, Paige Prostate displayed an optimal sensitivity (1.0; CI 0.93–1.0) and NPV (1.0; CI 0.91–1.0).
• The AI identified 4 cases containing foci of malignancy not previously diagnosed by the local or central pathologists as malignant.